Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Endocrinology | Family Medicine | Internal Medicine | Nursing | Pharmacy | Conference News

Back to Journal Articles

ADA: Impact of Insulin Glargine on Cardio Outcomes Negligible

Last Updated: June 12, 2012.

 

Modest weight gain and increase in severe hypoglycemia when compared to standard care

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The use of insulin glargine to normalize fasting blood glucose levels is not associated with improvements in cardiovascular outcomes compared with standard care, according to a study published online June 11 in the New England Journal of Medicine to coincide with presentation at the American Diabetes Association's 72nd Scientific Sessions, held from June 8 to 12 in Philadelphia.

TUESDAY, June 12 (HealthDay News) -- The use of insulin glargine to normalize fasting blood glucose levels is not associated with improvements in cardiovascular outcomes compared with standard care, according to a study published online June 11 in the New England Journal of Medicine to coincide with presentation at the American Diabetes Association's 72nd Scientific Sessions, held from June 8 to 12 in Philadelphia.

Hertzel C. Gerstein, M.D., from McMaster University and Hamilton Health Sciences in Canada, and colleagues from the Outcome Reduction with an Initial Glargine Intervention trial randomized 12,537 adults (mean age, 63.5 years) with cardiovascular risk factors and impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine or standard care. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (first coprimary outcome) and these events plus revascularization or hospitalization for heart failure (second coprimary outcome). The authors also looked at between-group differences in microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers.

During a median of 6.2 years of follow-up, the researchers found that there were similar rates of incident cardiovascular outcomes for the insulin-glargine and standard-care groups (first coprimary outcome, 2.94 and 2.85 per 100 person-years, respectively [P = 0.63] and second coprimary outcome, 5.52 and 5.28 per 100 person-years, respectively [P = 0.27]). Approximately three months after therapy was stopped, new diabetes was diagnosed in 30 and 35 percent, respectively, of participants without baseline diabetes (odds ratio, 0.80; 95 percent confidence interval, 0.64 to 1.00; P = 0.05). The rates of severe hypoglycemia per 100 person-years were 1.00 and 0.31, respectively. In the insulin-glargine group the median weight increased by 1.6 kg, whereas in the standard-care group weight declined by 0.5 kg. No significant difference was noted in the incidence of cancers between the groups.

"When used to target normal fasting plasma glucose levels for more than six years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers," the authors write. "Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight."

The study was supported by Sanofi; several authors disclosed financial ties to pharmaceutical companies, including Sanofi-Aventis, which manufactures insulin glargine.

Abstract
Full Text
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Genital Reconstruction Reduces Pain, Restores Pleasure Next: Breast Cancer Incidence Down With Metformin Use in Diabetes

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.